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INTRODUCTION
Women with breast cancer (BC) remains the second lethal form of cancer disrupts the female's lives over the world after lung cancer (Torre, Bray, Siegel, & Ferlay, 2015; Yedjou et al., 2019) . BC affects more than one woman in ten globally (Yedjou et al., 2019) resulted in nearly over 2 million cases of BC annually (MOKBEL & MOKBEL, 2019) .
In Egypt, 32% of all newly diagnosed cancer among women in B C with a high mortality rate represents 15% of worldwide deaths per year (Ibrahim, Khaled, Mikhail, Baraka, & Kamel, 2014; Yehia Ibrahim, 2019) .
Molecular subtypes of BC are essential for patient diagnosis, treatment decision and patient outcomes (Bouchal et al., 2019) . BC are categorized into four molecular subtypes by three cell membrane markers; estrogen receptor (ER), progesterone receptor (PR), as well as the human epidermal growth factor receptor (HER2 -) that is crucial for overall survival (OS) prediction (Nielsen et al., 2004; Shuch, Brian; Linehan, B. W. M.L.; Srivasan, 2012) . The molecular intrinsic subtypes include luminal A (ER + and/or PR + and HER2 -), luminal B (ER + and/or PR + and HER2 + ), HER2 + (ER -, PRand HER2 + ), and triplenegative (ER -, PRand HER2 -).
The increase of fast food and non-healthy diets are considered threats for increasing obesity among Egyptian women and worldwide (Almuhanna, Alsaif, Alsaadi, & Almajwal, 2014) that responsible for developing various tumor forms, including breast cancer and colon cancer (Chu et al., 2019; Tiwari et al., 2019) . Several studies have found that obesity can be considered as a predictor for poor prognosis in preand postmenopausal BC women (Chan, Sc, Norat, & Ph, 2015; Tiwari et al., 2019) .
Obesity is identified as over fat accumulation in the adipose tissues (AT) which constitute mainly of cells known as adipocytes (Engin, Engin, & Gonul, 2019) . Any dysfunction in AT physiological role can promote excess weight (Chu et al., 2019) , which in turn affects BC by releasing certain bioactive proteins collectively termed adipokines that contribute to proliferation and migration of cancer cells that influence the poor prognosis in patients with BC (Guerro-Millo, 2004) .
Caveolin-1(Cav-1) protein is the primary component of the caveola (lipid raft) membrane (Chang et al., 2017; Nouh et al., 2011) . Cav-1 belongs to a group of Cav-2 and Cav-3 caveolins (Cohen, Hnasko, Schubert, & Lisanti, 2004; Williams & Lisanti, 2004; Williams et al., 2006) . It is highly expressed by AT especially adipocytes of fatty mammary pads (Williams et al., 2006) . Some studies considered Cav-1 protein as adipokine and exerts an effect on the role of the adjacent cell in the microenvironment (Chang et al., 2017) . Cav-1, 22 kDa (Catalán et al., 2008) has been demonstrated to be elevated by numerous kinds of human cancers including kidney, liver, breast, colon (Nwosu, Ebert, Dooley, & Meyer, 2016) . This elevated Cav-1 level built caveola which contains different proteases that stimulate extracellular matrix (ECM) degradation and promote cancer motility and invasion. (Victor, Anbalagan, Mohamed, Sloane, & Cavallo-medved, 2011) . In addition, secreted Cav-1 proteins were increased by obesity in mice model. The objective of this study was to determine the expression levels of Cav-1 protein in AT of non-obese vs. obese BC patients by IHC and immunoblotting.
MATERIALS AND METHOD : Patients' Samples
For the purpose of patients' enrolment in this study, Institutional Review Board (IRB) approval was obtained before the surgery and the protocol was approved by the ethics committee of Ain Shams University (Cairo, Egypt). Each patient signed a written consent form prior to participation, including agreements for enrolment in this study and publication of data. Patients who were pre-operatively diagnosed as BC cases by clinical examination, mammography, ultrasound and Trucut biopsy in breast clinic of Ain Shams University hospitals have participated in the present study. The human AT was collected from 20 participants undergoing modified radical mastectomy (MRM) or conservative surgery. Patients enrolled in our study were classified into two subgroups; non-obese BC patients (n=5) and obese BC patients (n=15).
Sample Collection and Handling:
Within hr as soon as possible after Dr. El-Shinawi's surgery AT specimens were carried to the laboratory from the operating room. (Fig.1A )Each tissue specimen was divided into 2 parts; one fixed at 10% PBS-formalin buffered solution for IHC diagnosis and the second part was processed for further biochemical and molecular studies.
Culture of Tumor-Associated Adipose Tissue (TAAT) Isolated During Breast Surgery:
The method of maintaining the tissue specimens was performed under an aseptic condition. ,TAAT provided by the surgeon during breast cancer surgery was transferred directly to the lab ( Fig 1A) . AT specimens ( Fig 1B) were washed twice with Phosphate Buffered Saline (PBS) and a total amount of about 200-300 mg AT was sliced into very small pieces. The TAAT fragments were distributed equally into a tissue culture dish (Greiner bio-one, Frickenhausen, Germany) supplemented with 2 ml DMEM-F12 media containing 10% FBS and incubated for 24 h in the incubator. The media were discarded was discarded on the next morning, 1 ml serum-free media were added and incubated for 24 h in a humidified atmosphere of 5% CO2 at 37 º. Finally, TAAT conditioned media was collected and stored at -80ºC for cytokine profiling. Alternatively, TAAT explants were kept at -80°C for future experiments.
Profiling of the Secretions of TAAT-CM Using Human Cytokine Array:
Ray-Bio cytokine antibody array-C3 (RayBiotech, Inc. GA, USA) was used to detect all different adipokines in ATCM according to the manufacturer's instructions. Briefly, the TAAT-CM was 5-fold concentrated using Amicon Ultracell10K filters (Millipore, Billerica, MA). The cytokine array membrane is incubated with 2 ml blocking buffer for 1 h at RT followed by incubation overnight at 4°C with ATCM. Finally, the membrane was probed with a biotinylated antibody cocktail overnight at 4°C followed by incubation with HRP-conjugated streptavidin overnight at 4°C. ImageJ software was used to evaluate the adipokines signal intensity. Each adipokine signal intensity value is presented as mean ± SEM (n = 5).
Immunohistochemistry (IHC):
Immunohistochemical staining was performed using 5 µm paraffin adipose tissue sections sliced with a microtome and mounted on positively charged slides as described by the author (Nouh et al., 2011) . In brief, AT sections were first de-waxed in xylene clearing agent and hydrated through descending serial dilutions of ethanol (100%, 90%, 70%, and 50%) (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). For the heatinduced antigen retrieval process, slides were incubated in pre-heated retrieval buffer in water steamer for 30 min, followed by cooling at room temperature for 30 min. Endogenous peroxidase activity was blocked for 10 min using Dako Dual Endogenous Enzyme Block. After blocking, adipose tissue sections were incubated overnight at 4 °C with 1: 150 diluted primary antibody Cav-1 (BD Biosciences, San Diego, CA, USA). After washing, the slides were incubated with 100 µl horseradish peroxidase (HRP) linked secondary anti-mouse (EnVision + Dual Link System, Dako, Denmark) for 45 min at room temperature.
IHC signal development was carried out by adding 100 µL of the chromogen 3-3ʹdiaminobenzidine (DAB+) diluted 1:50 in substrate buffer for 10-15 min depending on the appearance of a brown color. Negative control slides were run in parallel in which the primary antibody was omitted. Finally, tissue specimens were washed in phosphate-buffered saline (PBS), the nuclei were counterstained with Mayer's haematoxylin for a minute, washed in tap water following dehydration through ascending ethanol serial dilutions (70%, 90%, and 100%) and clearing steps through xylene and the specimens were mounted using Permount ® ( Fisher Scientific, Pittsburgh, PA, USA) and air-dried overnight for examination by light microscopy (Olympus, CX41, Japan). The stained area fractions were analyzed semi-quantitatively using ImageJ software (National Institutes of Health, MD, USA).
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Immunoblotting:
AT of non-obese and obese fresh BC patients obtained by doctor El-shinawi was lysed in radioimmunoprecipitation assay buffer (RIPA buffer) [25 mM Tris HCL pH 7.6, 150 mM NaCl, 1% Triton X-100, 1% Sodium deoxycholate and 0.1% SDS (Sigma-Aldrich, St. Louis, MO, USA)] and then centrifuged for 10 minutes at 10,000 × g at 4°C. After blocking for 1 hr with 5% nonfat dry milk in TBS-0.5% Tween 20 (TBST), the membrane was probed with primary antibody against 1:5000 dilution of cav-1 (BD Biosciences, San Diego, CA, USA) overnight at 4 ˚C on shaker and then washed and incubated with secondary antibody conjugated with 1:10,000 diluted horseradish peroxidase (Santa Cruz Biotech, CA, USA) for 1 hr at room temperature. After washing, bound antibodies were visualized by using Pierce Enhanced Chemiluminescence immuno-blotting substrate (ECL) (Thermo Scientific, ON, Canada) according to the manufacturer's protocol, and analyzed with ImageJ software (National Institutes of Health, Bethesda, MA, USA), which quantifies the density of each band using β-actin (Santa Cruz Biotech, CA, USA) as a loading control.
Statistical Analysis:
The data are analyzed using IBM SPSS version 15.0 (SPSS, Chicago, IL, USA) and presented as mean ± SEM. Differences among patients were evaluated using Chisquare and Student's t-test. Pearson's Rank coefficient test was used to assess the associations with patient clinical data. Two-tailed p < 0.05 was considered significant.
RESULTS Clinical and Pathological Characterization of BC Patients:
Clinical and pathological characteristics of obese patients (n =15) and non-obese (n =5) patients who participated in the study are presented in Table 1 . The mean age of obese patients was 52.5 ± 3.9 which ranged from 34 to 71 years while the mean age of non-obese patients was 52.6 ± 3.28 which ranged from 43 to 62 years. Tumor size measurements revealed that 61.54% of obese patients exhibited tumor masses less than or equal 4 cm and 38.46% of them exhibited tumor masses greater than 4 cm, whereas, in the non-obese group, 50% of the patients had a tumor size less than or equal 4 and 50% of them having a tumor greater than 4. The tumor grade analysis among obese patients revealed that 78.57% were classified as grade II (G2) and 21.43% were grade III (G3), while 100% classified as grade 2 (G2) in nonobese. Among obese patients, 78.57% were negative for lymph vascular invasion and 21.43% were positive for lymph vascular invasion. While 100% of non-obese (control) patients were negative for lymph vascular invasion. All obese patients who underwent surgery had positive metastatic lymph nodes: 71.43% had had lymph nodes less than or equal 4 positive lymph nodes and 28.75% had greater than 4 positive metastatic lymph nodes while in non-obese patients, 100% had ≤ 4 lymph nodes. ER, PR and HER-2 status were assessed as negative and positive for all obese and non-obese patients. Positive staining for ER, PR, and HER-2 was detected in 53.33%, 60% and 33.33% obese patients, respectively. Whereas, the positive staining for ER, PR in non-obese patients were 33.3% and 33.3%, respectively. 
Profiling of Adipokines Secreted From AT Explants BC Patients:
ATCM secreted of AT explants from BC patients after 24 h was subjected to RayBioTM cytokine antibody array 3 cytokines (Fig. 2) . The secreted ATCM from BC patients showed that the monocyte chemoattractant protein (MCP-1), interleukin (IL-6), and interleukin (IL-8) cytokines are the highest adipokines secreted by AT. The cytokines array image was quantified using ImageJ software.
Overexpression of Caveolin-1 Protein in AT of Non-Obese Versus Obese BC Patients:
Assessment of the expression of Cav-1 in paraffin-embedded tissue sections of non-obese versus obese AT patients with BC using IHC to stain Cav-1 (Figs. 3A, B& C) . A statistically significant difference between the expressions of Cav-1 protein was detected in obese compared to nonobese tissues (P < 0.05).
Caveolin-1 Protein Level Is Higher in the AT of Obese Than Non-Obese Breast Cancer Patients:
Immunoblotting analysis was used for assessment of Cav-1 expression in tissue lysates of obese vs. non-obese BC adipose tissue patients to confirm IHC results. Western Blot results (Figs. 4A, B& C) showed the expression of Cav-1 (22 KDa) was significantly (p < 0.05) overexpressed in obese (n = 10) compared to non-obese patients (n = 5) by ImageJ software and normalized against the loading control B-actin. 
DISCUSSION
In the present study, our data further demonstrated that the highest secreted adipokines are IL-6, IL-8, and MCP-1 and there is a high expression of Cav-1 protein level in adipose breast carcinoma tissues by adipocytes of obese vs. non-obese.
As mentioned by the author Catalan that there is a positive correlation between the secretion of MCP-1 and Cav-1 (Catalán et al., 2008) . Our study also confirmed this where we found more expression of MCP-1 by obese breast cancer patients. In other words, we found that there is an increase also in secreted Cav-1 in addition to MCP-1 but the secretion increased significantly in obese patients compared to non-obese patients.
Furthermore, the expression of IL-6 found to be correlated with the expression of caveolin-1 and poor prognosis in breast cancer patients (Podar et al., 2003) .
In the caveolae, the membrane regions which is rich in cholesterols and glycosphingolipids characterized by obtaining the main protein Cav-1 (Chang et al., 2017) . Besides previous studies that Cav-1 implicated in endocytosis and signaling, there is a wide variety of studies showed that Cav-1 is altered in several cancer types such as liver, colon, breast, kidney, prostate, and plays diverse functions in cancer development by secretion of MMPS which degrade ECM (Nwosu et al., 2016) . In addition, Cav1 promote breast cancer development and metastasis by affecting various aspects of epithelial-mesenchymal transition (EMT) (Bailey & Liu, 2008; Gai, Lu, Tu, Liang, & Zheng, 2014; Goetz, Lajoie, Wiseman, & Nabi, 2008; Qian et al., 2019) .
As mentioned in the study conducted by Taher and colleagues that human and mouse prostate cancer cell lines promotes cancer cell survival and growth in vitro via secreting Cav-1 and thus considered as a biomarker and therapeutic target for cancer treatment (Tahir et al., 2001) .
It should be mentioned that in obesity, adipocytes are hypertrophied with a change in the adipokine secretiv e profile of obese adipose tissue. Our findings agree with a study conducted by Chang and co-workers that obesity changed Cav-1 secretion as reported that adipose tissues from normal chow diet-fed mice far less than that secreted high-fat diet-fed mice and that lack of Cav-1 has been linked to loss of fat tissue (Chang et al., 2017) . In addition, they found that ERK1/2 might play a role in obese subjects in comparison to non-obese subjects. Interestingly, inhibition of ERK1/2 activation in obese patients with PD98059, a MEK1/2 inhibitor, prevented the Cav-1 secretion (Chang et al., 2017) .
Our findings are in accordance with a study that showed that Cav-1 expression may contribute to the formation of more caveolae the membrane lipid raft that encloses different non-active proteases, cytokines, inflammatory mediators involved in cancer motility, invasion and metastasis. In addition, we found that Cav-1 secretion in CAAT is markedly associated with obesity, so the high expression of cav-1 may emerge as a biomarker for obese breast cancer patients and its targeting may represent a therapeutic strategy. However, our findings should be verified in a large group of breast cancer patients.
